The Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or Nintedanib

Vasakova, M. K.Mogulkoc, N.Kramer, M.Doubkova, M.Plackova, M.Mueller, V.Studnicka, M. J.2024-08-252024-08-2520231073-449X1535-4970https://hdl.handle.net/11454/101117International Conference of the American-Thoracic-Society (ATS) -- MAY 19-24, 2023 -- Washington, DC[No abstract available]eninfo:eu-repo/semantics/closedAccessThe Impact of Switching to a Second Antifibrotic Therapy on Outcomes in Patients With IPF in the Empire Registry Treated With Pirfenidone or NintedanibConference Object207WOS:000995814702432Q1